eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer

摘要: To identify novel therapeutic targets for non-small cell lung cancer (NSCLC), we conducted an integrative study in the following 3 stages: (i) identification of potential target gene(s) through shRNA functional screens 2 independent NSCLC lines; (ii) validation clinical relevance identified using public databases; and (iii) investigation targeting vitro. A semi-genome-wide screen was performed NCI-H358 cells, integrated with data from our previous NCI-H460 cells. Among genes screens, 24 were present both cells considered targets. genes, focused on eIF2β, which is a subunit heterotrimeric G protein EIF2 functions as transcription initiation factor. The eIF2β highly expressed lines compared normal bronchial epithelial gene copy number analyses revealed that amplified subset lines. Gene expression analysis Cancer Genome Atlas (TCGA) dataset significantly upregulated tissues corresponding tissues. Furthermore, high correlated poor survival patients adenocarcinoma, shown other cohorts publicly available online tools. RNAi-mediated depletion suppresses growth independently p53 mutation status, part G1 cycle arrest. Our suggest cancer.